เชิงอรรถและอ้างอิง ของ Anti-vascular_endothelial_growth_factor_therapy

  1. ↑ Bergers, G; Hanahan, D (2008-08). "Modes of resistance to anti-angiogenic therapy". Nat. Rev. Cancer. 8 (8): 592–603. doi:10.1038/nrc2442. PMC 2874834. PMID 18650835. the benefits are at best transitory and are followed by a restoration of tumour growth and progression. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  2. ↑ Ebos, John; Lee, Christina R; Cruz-Munoz, William; Bjarnason, Georg A; Christensen, James G; Kerbel, Robert S (2009-03). "Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis". Cancer Cell. 15 (3): 232–239. doi:10.1016/j.ccr.2009.01.021. PMID 19249681. สืบค้นเมื่อ 2012-10-22. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  3. ↑ Pàez-Ribes, Marta; Allen, Elizabeth; Hudock, James; Takeda, Takaaki; Okuyama, Hiroaki; Viñals, Francesc; Inoue, Masahiro; Bergers, Gabriele; Hanahan, Douglas; Casanovas, Oriol (2009-03). "Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis". Cancer Cell. 15 (3): 220–231. doi:10.1016/j.ccr.2009.01.027. PMC 2874829. PMID 19249680. สืบค้นเมื่อ 2012-10-22. Check date values in: |date= (help)
  4. ↑ Ledermann, Jonathan A; Embleton, Andrew C; Raja, Fharat; Perren, Timothy J; Jayson, Gordon C; Rustin, Gordon J S; Kaye, Stan B; Hirte, Hal; Eisenhauer, Elizabeth; Vaughan, Michelle; Friedlander, Michael; González-Martín, Antonio; Stark, Daniel; Clark, Elizabeth; Farrelly, Laura; Swart, Ann Marie; Cook, Adrian; Kaplan, Richard S; Parmar, Mahesh K B (2016). "Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6) : a randomised, double-blind, placebo-controlled phase 3 trial". The Lancet. 387 (10023): 1066–1074. doi:10.1016/S0140-6736(15)01167-8. ISSN 0140-6736. PMID 27025186.
  5. 1 2 Braithwaite, Tasanee; Nanji, Afshan A.; Lindsley, Kristina; Greenberg, Paul B. (2014-05-01). "Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion". The Cochrane Database of Systematic Reviews (5): CD007325. doi:10.1002/14651858.CD007325.pub3. ISSN 1469-493X. PMC 4292843. PMID 24788977.
  6. ↑ "FDA Approves New Biologic Treatment for Wet Age-Related Macular Degeneration". FDA News & Events. 2006-06-30. สืบค้นเมื่อ 2013-04-17.
  7. ↑ Brown, David M.; Michels, Mark; Kaiser, Peter K.; Heier, Jeffrey S.; Sy, Judy P.; Ianchulev, Tsontcho; Anchor Study, Group (2009). "Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study". Ophthalmology. 116 (1): 57–65. doi:10.1016/j.ophtha.2008.10.018. PMID 19118696.
  8. ↑ Rosenfeld, Philip J.; Brown, David M.; Heier, Jeffrey S.; Boyer, David S.; Kaiser, Peter K.; Chung, Carol Y.; Kim, Robert Y.; Marina Study, Group (2006). "Ranibizumab for Neovascular Age-Related Macular Degeneration". New England Journal of Medicine. 355 (14): 1419–31. doi:10.1056/NEJMoa054481. PMID 17021318.
  9. ↑ Raftery, J.; Clegg, A.; Jones, J.; Tan, S. C.; Lotery, A. (2007). "Ranibizumab (Lucentis) versus bevacizumab (Avastin) : modelling cost effectiveness". British Journal of Ophthalmology. 91 (9): 1244–6. doi:10.1136/bjo.2007.116616. PMC 1954941. PMID 17431015.
  10. ↑ "Patent Docs: Genentech Acts to Halt Off-label Use of Avastin® for Age-related Macular Degeneration". Patent Docs. 2007-10-21. คลังข้อมูลเก่า เก็บจาก แหล่งเดิม เมื่อ 2016-03-04. Unknown parameter |deadurl= ignored (help)
  11. ↑ อโนมา สอนบาลี (2014). "โอกาสและทางเลือก สำหรับผู้ป่วยโรคจุดภาพชัดจอตา" (PDF). จุลสารโครงการประเมินเทคโนโลยีและนโยบายด้านสุขภาพ ปีที่ 5 ฉบับที่ 17 กรกฎาคม-กันยายน 2555. โครงการประเมินเทคโนโลยีและนโยบายด้านสุขภาพ กรมอนามัย กระทรวงสาธารณสุข. ประสิทธิภาพ ความปลอดภัย และข้อบ่งชี้, หน้า 8-9. คลังข้อมูลเก่า เก็บจาก แหล่งเดิม (PDF) เมื่อ 2018-07-18. สืบค้นเมื่อ 2018-05-28.CS1 maint: uses authors parameter (link) CS1 maint: ref=harv (link) อ้างอิง
    • "Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results". Ophthalmology. Elsevier. 119 (7). 2012-07. Check date values in: |date= (help)
    • Chakravarthy, U. และคณะ (2012-07). "Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial". Ophthalmology. Elsevier. 119 (7). Check date values in: |year= (help); Explicit use of et al. in: |authors= (help)CS1 maint: uses authors parameter (link)
  12. ↑ Shah, DK; Menon, KM; Cabrera, LM; Vahratian, A; Kavoussi, SK; Lebovic, DI (2010-04). "Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro". Fertil. Steril. 93 (6): 2042–7. doi:10.1016/j.fertnstert.2009.02.059. PMC 2847675. PMID 19342033. Check date values in: |date= (help)CS1 maint: uses authors parameter (link)
  13. ↑ Simha, A; Braganza, A; Abraham, L; Samuel, P; Lindsley, K (2013). "Anti-vascular endothelial growth factor for neovascular glaucoma". Cochrane Database Syst Rev. 10: CD007920. doi:10.1002/14651858.CD007920.pub2. PMC 4261636. PMID 24089293.CS1 maint: uses authors parameter (link)
  14. ↑ Virgili, G; Parravano, M; Evans, JR; Gordon, I; Lucenteforte, E (2017). "Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis". Cochrane Database Syst Rev. 6: CD007419. doi:10.1002/14651858.CD007419.pub5. PMID 28639415.CS1 maint: uses authors parameter (link)

แหล่งที่มา

WikiPedia: Anti-vascular_endothelial_growth_factor_therapy http://www.cell.com/cancer-cell/abstract/S1535-610... http://www.cell.com/cancer-cell/abstract/S1535-610... http://www.nature.com/nrc/journal/v8/n8/abs/nrc244... http://patentdocs.typepad.com/patent_docs/2007/10/... http://www.fda.gov/NewsEvents/Newsroom/PressAnnoun... //pubmed.ncbi.nlm.nih.gov/17021318 //pubmed.ncbi.nlm.nih.gov/17431015 //pubmed.ncbi.nlm.nih.gov/18650835 //pubmed.ncbi.nlm.nih.gov/19118696 //pubmed.ncbi.nlm.nih.gov/19249680